Current progress toward eradicating Helicobacter pylori in East Asian countries: Differences in the 2013 revised guidelines between China, Japan, and South Korea

Table 1 Indications for Helicobacter pylori eradication in 2013 guidelines

	Indications
China	Strongly recommended
	Peptic ulcer (regardless of activeness or complications)
	Gastric MALT lymphoma
	Recommended
	Chronic gastritis with dyspepsia
	Chronic gastritis with mucosal atrophy/erosion
	Early gastric cancer resected endoscopically or by subtotal gastrectomy
	Long-term use of proton pump inhibitor
	Family history of gastric cancer
	Planning to take long-term NSAIDs (including low-dose aspirin)
	Iron deficiency anemia of unknown causes
	Idiopathic thrombocytopenic purpura
	Other H. pylori-related diseases (lymphocytic gastritis, gastric hyperplastic polyps, Ménétrier disease, etc.)
	Requested by individual patient
Japan	Approved by the Japanese national health insurance system
	Peptic ulcer disease
	After resection of early gastric cancer
	Gastric MALT lymphoma
	Idiopathic thrombocytopenic purpura
	H. pylori-related gastritis
South Korea	Strongly recommended
	Peptic ulcer disease
	Low-grade gastric MALT lymphoma
	After resection of early gastric cancer
	Recommended
	Chronic atrophic gastritis or intestinal metaplasia
	Family history of gastric cancer
	Functional dyspepsia
	Long-term aspirin/NSAIDs medication with history of peptic ulcer disease
	Idiopathic thrombocytopenic purpura

H. pylori: Helicobacter pylori; MALT: Mucosa-associated lymphoid tissue; NSAIDs: Nonsteroidal anti-inflammatory drugs.